Xilio Therapeutics (XLO) Competitors

$8.81 +1.05 (+13.53%)

Closing price 04:00 PM Eastern

Extended Trading

$8.75 -0.06 (-0.68%)

As of 07:38 PM Eastern

XLO vs. DTIL, OGI, TKNO, LFCR, and CRBU

Should you buy Xilio Therapeutics stock or one of its competitors? MarketBeat compares Xilio Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xilio Therapeutics include Precision BioSciences (DTIL), Organigram Global (OGI), Alpha Teknova (TKNO), Lifecore Biomedical (LFCR), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry.

How does Xilio Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Xilio Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.64	-$45.72M	-$3.67	N/A
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A

In the previous week, Precision BioSciences and Precision BioSciences both had 3 articles in the media. Precision BioSciences' average media sentiment score of 0.94 beat Xilio Therapeutics' score of 0.81 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xilio Therapeutics has a net margin of -58.52% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -85.37% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Xilio Therapeutics	-58.52%	-354.12%	-28.73%

Precision BioSciences presently has a consensus target price of $36.33, indicating a potential upside of 348.01%. Xilio Therapeutics has a consensus target price of $28.00, indicating a potential upside of 217.82%. Given Precision BioSciences' higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Precision BioSciences has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market.

Summary

Precision BioSciences beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Organigram Global?

Xilio Therapeutics (NASDAQ:XLO) and Organigram Global (NASDAQ:OGI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Organigram Global has higher revenue and earnings than Xilio Therapeutics. Organigram Global is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A
Organigram Global	$279.99M	0.55	-$17.70M	-$0.13	N/A

In the previous week, Organigram Global had 9 more articles in the media than Xilio Therapeutics. MarketBeat recorded 12 mentions for Organigram Global and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.81 beat Organigram Global's score of 0.18 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organigram Global	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organigram Global has a net margin of -9.22% compared to Xilio Therapeutics' net margin of -58.52%. Organigram Global's return on equity of -13.49% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-354.12%	-28.73%
Organigram Global	-9.22%	-13.49%	-8.99%

Xilio Therapeutics currently has a consensus target price of $28.00, indicating a potential upside of 217.82%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Organigram Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Xilio Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market. Comparatively, Organigram Global has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Organigram Global beats Xilio Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Alpha Teknova?

Alpha Teknova (NASDAQ:TKNO) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Alpha Teknova has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the broader market.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alpha Teknova has a net margin of -41.07% compared to Xilio Therapeutics' net margin of -58.52%. Alpha Teknova's return on equity of -24.32% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-41.07%	-24.32%	-16.34%
Xilio Therapeutics	-58.52%	-354.12%	-28.73%

Alpha Teknova presently has a consensus target price of $8.00, suggesting a potential upside of 115.05%. Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 217.82%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Xilio Therapeutics is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Alpha Teknova has higher earnings, but lower revenue than Xilio Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Teknova	$40.52M	4.92	-$17.26M	-$0.32	N/A
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A

In the previous week, Alpha Teknova had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 5 mentions for Alpha Teknova and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.81 beat Alpha Teknova's score of 0.41 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alpha Teknova beats Xilio Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xilio Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market.

In the previous week, Lifecore Biomedical had 1 more articles in the media than Xilio Therapeutics. MarketBeat recorded 4 mentions for Lifecore Biomedical and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.81 beat Lifecore Biomedical's score of 0.40 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has a net margin of -25.43% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -354.12% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-25.43%	-1,643.15%	-14.40%
Xilio Therapeutics	-58.52%	-354.12%	-28.73%

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Xilio Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.32	-$35.26M	-$0.94	N/A
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A

Lifecore Biomedical presently has a consensus target price of $6.00, suggesting a potential upside of 31.87%. Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 217.82%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xilio Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Lifecore Biomedical beats Xilio Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Xilio Therapeutics compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Xilio Therapeutics has higher revenue and earnings than Caribou Biosciences. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	19.02	-$148.12M	-$1.42	N/A
Xilio Therapeutics	$43.77M	1.20	-$35.04M	-$5.49	N/A

Caribou Biosciences has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Caribou Biosciences presently has a consensus target price of $8.67, suggesting a potential upside of 304.98%. Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 217.82%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Caribou Biosciences is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Caribou Biosciences had 18 more articles in the media than Xilio Therapeutics. MarketBeat recorded 21 mentions for Caribou Biosciences and 3 mentions for Xilio Therapeutics. Xilio Therapeutics' average media sentiment score of 0.81 beat Caribou Biosciences' score of 0.24 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xilio Therapeutics has a net margin of -58.52% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Xilio Therapeutics	-58.52%	-354.12%	-28.73%

Summary

Caribou Biosciences beats Xilio Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Xilio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XLO vs. The Competition

Export

Metric	Xilio Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.68M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-2.48	18.98	20.89	25.59
Price / Sales	1.20	180.83	523.74	63.24
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	1.21	6.74	9.86	6.70
Net Income	-$35.04M	$24.11M	$3.55B	$333.77M
7 Day Performance	12.80%	0.08%	-0.33%	0.45%
1 Month Performance	2.56%	0.84%	1.34%	4.06%
1 Year Performance	-25.97%	78.10%	41.10%	36.24%

Xilio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XLO Xilio Therapeutics	3.0173 of 5 stars	$8.81 +13.5%	$28.00 +217.8%	-51.8%	$52.68M	$43.77M	N/A	70	Earnings Report High Trading Volume
DTIL Precision BioSciences	2.4049 of 5 stars	$7.45 -2.4%	$36.33 +387.7%	+62.3%	$196.88M	$34.26M	N/A	200	Gap Down
OGI Organigram Global	1.0306 of 5 stars	$1.39 flat	N/A	-10.1%	$195.67M	$185.07M	9.93	1,139	News Coverage Earnings Report
TKNO Alpha Teknova	2.448 of 5 stars	$3.74 +4.2%	$8.00 +113.9%	-42.0%	$192.46M	$40.52M	N/A	240
LFCR Lifecore Biomedical	1.7329 of 5 stars	$5.16 +0.6%	$6.00 +16.3%	-35.3%	$192.26M	$128.87M	N/A	690

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XLO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xilio Therapeutics (XLO) Competitors

XLO vs. DTIL, OGI, TKNO, LFCR, and CRBU

How does Xilio Therapeutics compare to Precision BioSciences?

Summary

How does Xilio Therapeutics compare to Organigram Global?

Summary

How does Xilio Therapeutics compare to Alpha Teknova?

Summary

How does Xilio Therapeutics compare to Lifecore Biomedical?

Summary

How does Xilio Therapeutics compare to Caribou Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xilio Therapeutics (XLO) Competitors

XLO vs. DTIL, OGI, TKNO, LFCR, and CRBU

How does Xilio Therapeutics compare to Precision BioSciences?

Which has better valuation & earnings, DTIL or XLO?

Does the media prefer DTIL or XLO?

Is DTIL or XLO more profitable?

Do analysts prefer DTIL or XLO?

Do institutionals & insiders believe in DTIL or XLO?

Which has more volatility & risk, DTIL or XLO?

Summary

How does Xilio Therapeutics compare to Organigram Global?

Do institutionals and insiders believe in XLO or OGI?

Which has higher earnings & valuation, XLO or OGI?

Does the media refer more to XLO or OGI?

Is XLO or OGI more profitable?

Do analysts recommend XLO or OGI?

Which has more volatility & risk, XLO or OGI?

Summary

How does Xilio Therapeutics compare to Alpha Teknova?

Which has more volatility & risk, TKNO or XLO?

Do institutionals & insiders have more ownership in TKNO or XLO?

Is TKNO or XLO more profitable?

Do analysts rate TKNO or XLO?

Which has higher valuation & earnings, TKNO or XLO?

Does the media prefer TKNO or XLO?

Summary

How does Xilio Therapeutics compare to Lifecore Biomedical?

Which has more risk & volatility, LFCR or XLO?

Does the media prefer LFCR or XLO?

Is LFCR or XLO more profitable?

Do institutionals & insiders have more ownership in LFCR or XLO?

Which has stronger valuation and earnings, LFCR or XLO?

Do analysts rate LFCR or XLO?

Summary

How does Xilio Therapeutics compare to Caribou Biosciences?

Which has stronger valuation and earnings, CRBU or XLO?

Which has more risk & volatility, CRBU or XLO?

Do institutionals & insiders have more ownership in CRBU or XLO?

Do analysts rate CRBU or XLO?

Does the media prefer CRBU or XLO?

Is CRBU or XLO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XLO vs. The Competition

Xilio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools